DataMEDS AI, Inc.
MEDSHealthcareNASDAQMedical Distribution · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, DataMEDS AI, Inc. focuses on Medical Distribution services and products. DataMEDS AI, Inc. operates as a health IT company in the United States. The company carries a $2.8M market cap, placing it firmly in the micro-cap category. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers.
Market Cap
$2.8M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-48.19
EPS (Fwd)
—
ROE
—
ROA
-82.9%
Cash
$2.5M
Total Debt
$32.6M
Free CF
$2.4M
52W Change
-98.9%
Annual Financials
Cash vs Debt
Where MEDS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MEDS finished 82.48% below its 150-day moving average ($5.88) and 90.18% below its 200-day moving average ($10.49). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MEDS overbought or oversold?
At the September 3, 2026 close, MEDS's RSI(14) was 23.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MEDS has $2.5M in cash with $32.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $2.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Revenue has been uneven over recent years, ranging from $32.8M to $23.3M.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for DataMEDS AI, Inc. and its sector.